Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable safety profile with promising efficacy in phase 1 studies in patients with primary and secondary myelofibrosis (MF). This multicenter phase 2...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Komrokji, Rami S., Seymour, John F., Roberts, Andrew W., Wadleigh, Martha, To, L. Bik, Scherber, Robyn, Turba, Elyce, Dorr, Andrew, Zhu, Joy, Wang, Lixia, Granston, Tanya, Campbell, Mary S., Mesa, Ruben A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490373/
https://ncbi.nlm.nih.gov/pubmed/25762180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-484832
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares